13 Jun 2024

Research blog: How leukaemia cells thrive

In February 2024, a ground-breaking study was published in the esteemed journal Nature Communications (i), showcasing collaborative research efforts from a team of scientists, including three of our current and previously funded researchers Dr Sophie G. Kellaway, Dr Sandeep Potluri, and Dr Daniel J. L. Coleman. Their research focused on the pathways that lead to relapse in acute myeloid leukaemia – a significant hurdle in treatment.

Acute myeloid leukaemia (AML) is like a disruption in the orchestra of blood cell development, caused by genetic mutations. These mutations throw off the rhythm of normal growth, leading to the rapid multiplication of immature cells called blast cells. If left unchecked, these blast cells can overwhelm the body and become life-threatening.

While chemotherapy serves as the main treatment, it’s a bit like playing whack-a-mole—it can’t always catch all the leukaemia cells. Among those that escape are sneaky ones known as leukemic stem cells (LSCs). These crafty cells can lie low during treatment, only to spring back to life later on, causing a relapse.

But the big question remains: How do these cells manage to pull off their vanishing act and then reappear?

The study delves into how LSC’s in a subtype of acute myeloid leukaemia (AML), called t(8;21), restart their growth – causing relapse. The LSCs manage to cheat death by activating VEGF (vascular endothelial growth factor – this is a powerful factor that helps blood vessels grow) and IL-5 (these usually lead to maintenance of survival and functions of B cells and eosinophils – white blood cells) signalling pathways in an abnormal manner.

This finding is fascinating, it’s as if they’re flipping switches to turn on growth-promoting signals. And they don’t go solo—these pathways team up with certain proteins to coordinate the revival of LSCs while also ensuring they can keep renewing themselves.

It’s like they’ve cracked the code for eternal youth, but in a dangerous way. Understanding this intricate dance between LSCs and their signalling pathways could be the key to designing smarter treatments that target these pathways directly, aiming to cut off their supply lines and prevent leukaemia from making a comeback.

In conclusion, the recent study sheds light on the complex mechanisms underlying relapse in AML, uncovering how LSCs manage to reignite their growth. Understanding these processes is pivotal for developing targeted treatments that can intercept these pathways and halt relapse. This underscores the importance of continued support and funding for leukaemia research, as unravelling these mysteries is key to unlocking more effective therapies and ultimately stopping leukaemia in its tracks.

Discover our research blogs.

 

References:

(i) – Kellaway SG, Potluri S, Keane P, Blair HJ, Ames L, Worker A, Chin PS, Ptasinska A, Derevyanko PK, Adamo A, Coleman DJL, Khan N, Assi SA, Krippner-Heidenreich A, Raghavan M, Cockerill PN, Heidenreich O, Bonifer C. Leukemic stem cells activate lineage inappropriate signalling pathways to promote their growth. Nat Commun. 2024 Feb 14;15(1):1359. doi: 10.1038/s41467-024-45691-4. PMID: 38355578; PMCID: PMC10867020.

Related posts

Leukaemia UK is looking for volunteers for their Patient Experience Advisory Panel

4 June 2022

Leukaemia UK is looking for volunteers for their Patient Experience Advisory Panel

Leukaemia UK is committed to championing advancements in better treatments and care for all. We want to ensure the needs of patients are at the heart of everything we do, and that the voices of people affected by leukaemia and related conditions are being heard. That is why we are setting up a Patient Experience Advisory Panel.

Who’s Cooking Dinner? to return on Monday 19th September

1 August 2022

Who’s Cooking Dinner? to return on Monday 19th September

Who’s Cooking Dinner reveal all star Chef Line Up Famed Charity event to return on Monday 19th September For the past 24 years, Leukaemia UK, the leukaemia research charity dedicated…

Leukaemia UK drives forward progress for leukaemia research through five new John Goldman Fellowships for 2021

18 October 2021

Leukaemia UK drives forward progress for leukaemia research through five new John Goldman Fellowships for 2021

Leukaemia UK announces five new John Goldman Fellows for 2021 to accelerate progress and stop the disease devastating lives.

John Goldman Fellowships for 2023 now open

5 December 2022

John Goldman Fellowships for 2023 now open

Leukaemia UK is delighted to announce that we are funding more ground-breaking research in 2023, by continuing our investment in early career scientists and clinicians for our prestigious John Goldman…